Financial Data and Key Metrics Changes - The company reported revenues of $298,000, representing a 141% increase compared to the same quarter last year [6][4] - Gross profit totaled $187,000, which is 63% of revenues, marking a 69% increase from $111,000 in the same quarter last year [7] - Operating loss decreased by 10% to $1,800,000 compared to the same quarter a year ago [8] - Net loss available to common stockholders was $2,300,000, or a negative loss of $0.09 per share, which is a 15% improvement from the previous year's net loss of $2,000,000 [8] - Available cash increased to $3,300,000 from $220,000 as of March 31, 2025 [9] - Total liabilities decreased by 39% to $1,200,000 during the quarter [9] Business Line Data and Key Metrics Changes - The U.S. National distributor network increased sales by 192% year-over-year, contributing $198,000 or 67% of total revenue [4][6] - The introduction of the new Precise PRP product alongside Spring contributed to the revenue increase [6] Market Data and Key Metrics Changes - The Mexican veterinary health care market is projected to grow at a compounded annual growth rate of 11%, reaching $2.4 billion by February 2031 [3] - The U.S. animal health market is expected to double to $11.3 billion by February 2030, providing significant growth opportunities [24] Company Strategy and Development Direction - The company is focused on expanding the adoption of its flagship product, Spring, and increasing awareness of Precise PRP for treating osteoarthritis in animals [12] - Strategic partnerships have been formed, including collaborations with Commonwealth Markets and Piezo BioMembrane, to enhance product offerings and market reach [20][22] - The company is integrating AI technology with its veterinary products to create a global pet care ecosystem [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued strong sales momentum and market penetration for fiscal 2026 and beyond [24] - The company believes it is well-positioned to accelerate growth and expand into high-growth markets [24] Other Important Information - The company has recently qualified to trade on the OTCQX best market, enhancing visibility and liquidity for investors [11] - The commercialization of Spring and Precise PRP has received favorable feedback from veterinarians regarding their effectiveness [14] Q&A Session Summary - No questions were raised during the Q&A session, leading to the conclusion of the call [29][33]

Financial Data and Key Metrics Changes - PetVivo reported a record revenue of $1.1 million for fiscal year 2025, reflecting a 17% increase compared to the previous year [4][7] - Gross profit totaled $995,000, representing a gross margin of 87.8%, which is a slight decrease from 89.5% in fiscal year 2024 [8] - Operating expenses decreased by 21% to $9.1 million, primarily due to a strategic cost reduction program [8] - The net loss improved by 27% to $8 million, or $0.39 per share, compared to a net loss of $11 million, or $0.78 per share in fiscal year 2024 [9] Business Line Data and Key Metrics Changes - The expanding nationwide distributor network contributed $958,000 in sales, accounting for 86% of total revenues, with a 31% increase in their combined sales [7][8] - The company is focusing on increasing its market share in the companion animal segment while maintaining growth in the equine market [4][5] Market Data and Key Metrics Changes - The veterinary healthcare market in Mexico is projected to grow at a 6% CAGR, reaching nearly $2 billion by 2026, presenting a significant opportunity for PetVivo [3] - The U.S. animal health market is projected to double to $11.3 billion by 2030, providing substantial growth potential for the company [18] Company Strategy and Development Direction - The company aims to drive greater adoption of its products, particularly Spring and Precise PRP, by increasing awareness among key decision-makers in the veterinary field [11][12] - Strategic partnerships and collaborations, such as with Digital Landia and Commonwealth Markets, are expected to enhance product visibility and market penetration [16][24] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, citing strong sales momentum and market penetration expected in fiscal year 2026 [17] - The company is well-positioned to accelerate growth and expand into high-growth markets, driven by trends in pet ownership and advancements in veterinary care [18][19] Other Important Information - The company filed for an extension for its Form 10-K filing to allow auditors to complete their review, meaning all financial results presented are preliminary and unaudited [2][7] - The company raised net proceeds of $4.7 million from a Series B convertible preferred stock offering to support growth strategies [10] Q&A Session Summary Question: How much dilution do you expect from the conversion of the Series B preferred? - Management indicated that the conversion is on a one-to-one basis, with an additional 5 million shares expected if fully converted [30][32] Question: What is the average price per vial of the Spring injection that veterinarians are charging for canines? - The average charge by veterinary doctors is around $800 per joint, with variations between $500 to $1,200 depending on the complexity of the issue [36] Question: Can you talk a little bit about the human trials and their projected outcomes? - Management discussed ongoing studies with BioPiezo, showing promising results in small and large animals, with potential applications in the human market for osteoarthritis [46]

Financial Data and Key Metrics Changes - PetVivo reported a revenue growth of 17% for fiscal year 2025, totaling a record $1,100,000, driven largely by an expanding nationwide distributor network [4][8] - Gross profit was $995,000, representing 87.8% of revenues, which is a decrease from 89.5% in fiscal year 2024 [9] - Operating expenses decreased by 21% to $9,100,000, primarily due to a strategic cost reduction and restructuring program [9] - Net loss improved by 27% to $8,000,000 or $0.39 per share, compared to a net loss of $11,000,000 or $0.78 per share in fiscal year 2024 [10] Business Line Data and Key Metrics Changes - The expanding distributor network contributed $958,000 in sales, accounting for 86% of total revenues [4][8] - The company is focusing on increasing its market share in the companion animal market while maintaining growth in the equine market [4][5] Market Data and Key Metrics Changes - The veterinary healthcare market in Mexico is projected to grow at a 6% CAGR, reaching nearly $2,000,000,000 by 2026 [3] - The U.S. animal health market is projected to double to $11,300,000,000 by 2030, providing significant growth opportunities [19] Company Strategy and Development Direction - The company aims to drive greater adoption of its products, particularly Spring and Precise PRP, by increasing awareness among key decision-makers [12] - Strategic partnerships and collaborations, such as with Digital Landia, are expected to enhance product visibility and market penetration [17][24] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's position to accelerate growth and expand into high-growth markets [19] - The company anticipates strong sales momentum and market penetration in fiscal year 2026, supported by recent advancements and partnerships [18] Other Important Information - The company has strengthened its leadership team and commercial operations, appointing experienced executives to key positions [21][22] - A successful offering of $5,000,000 in Series B convertible preferred stock was completed to support growth strategies [11] Q&A Session Summary Question: How much dilution do you expect from the conversion of the Series B preferred? - The conversion is on a one-to-one basis, with an additional 5,000,000 shares expected if fully converted [28][30] Question: What is the average price per vial of the Spring injection that veterinarians are charging for canines? - The average charge is around $800 per joint, varying between $500 to $1,200 depending on the complexity of the problem [33][35] Question: Can you talk a little bit about the human trials and their projected path? - The company is excited about the results from small and large animal studies, with potential applications in the human market for osteoarthritis, which is valued at approximately $11,200,000,000 in the U.S. [43][44]